⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

JBCHEPHARM - Swing Trade Analysis with AI Signals

← Back to List

⭐ Rating: 3.2

Last Updated Time : 04 Aug 26, 08:47 am

Key Parameters

⭐ Swing Trade Rating: 3.2

Stock CodeJBCHEPHARM
Market Cap38,677 Cr.
Current Price2,409 ₹
High / Low2,526 ₹
Stock P/E56.6
Book Value251 ₹
Dividend Yield0.91 %
ROCE24.8 %
ROE18.4 %
Face Value1.00 ₹
DMA 502,260 ₹
DMA 2002,026 ₹
Chg in FII Hold1.45 %
Chg in DII Hold-1.97 %
PAT Qtr116 Cr.
PAT Prev Qtr179 Cr.
RSI61.0
MACD72.2
Volume0
Avg Vol 1Wk0
Low price1,603 ₹
High price2,526 ₹
PEG Ratio2.70
Debt to equity0.00
52w Index87.4 %
Qtr Profit Var-22.6 %
EPS42.0 ₹
Industry PE33.5

✅ Positive

JB Chemicals is experiencing a significant boost due to the recent merger with Torrent Pharma, resulting in increased profitability as indicated by the Q1FY27 PAT growth. The company's strong ROCE and ROE suggest efficient capital utilization and attractive returns for investors.

⚠️ Limitation

Despite positive news regarding the merger, the stock exhibits a high P/E ratio of 56.6, reflecting market optimism but potentially limiting upside potential. The recent decline in DII holdings and relatively low volume trading could indicate waning investor interest and increased volatility.

📉 Company Negative News

The company reported a substantial -22.6% quarter-on-quarter profit variance, suggesting concerns regarding the integration process or broader market headwinds impacting earnings. Recent news indicates a shift in board composition with the appointment of Shanti Ekambaram as an Additional Independent Director, which could introduce new complexities.

📈 Company Positive News

Torrent Pharma’s Q1FY27 profit increase of 3% to ₹566 crore driven by the JB merger represents favorable momentum for the combined entity and provides a positive catalyst for JB Chemicals shares. The listing of 4.19 crore shares from the merger indicates successful execution of the integration process, bolstering confidence in future performance.

🏭 Industry

The pharmaceutical sector is generally considered stable, but subject to regulatory changes, patent expirations, and competition. Mergers and acquisitions are common as companies seek scale and expanded market access within this highly regulated industry.

🧾 Conclusion

An optimal entry price would be around 2,350 ₹, considering the recent profit growth driven by the merger and a slightly reduced P/E ratio. For exit guidance, consider a target of 2,600 ₹ if the stock demonstrates sustained momentum following the integration. Ultimately, JBCHEPHARM represents a moderate swing trading candidate with potential gains but requires careful monitoring of the ongoing merger’s impact and broader market sentiment.

Technical Analysis
Fundamental Analysis

NIFTY 50 · Swing Trading

NEXT 50 · Swing Trading

MIDCAP · Swing Trading

SMALLCAP · Swing Trading